{"disease":{"id":"myelofibrosis-pmf","name":"myelofibrosis pmf"},"drugs":{"marketed":[{"drug_id":"part-c-met097","indication_name":"Treatment of Primary Myelofibrosis (PMF)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"(Part C) MET097","generic_name":"part-c-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Unknown","drug_class":"Unknown","quality_score":37,"revenue":null,"mechanism":"The exact mechanism of action is not specified on Wikipedia."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07362225","title":"MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"MPN Research Foundation","has_results":false},{"nct_id":"NCT07357727","title":"A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":460,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT03662126","title":"KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":385,"lead_sponsor_name":"Kartos Therapeutics, Inc.","has_results":false},{"nct_id":"NCT03441113","title":"Extended Access of Momelotinib in Adults With Myelofibrosis","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":237,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT02101268","title":"Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT03136185","title":"Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT06343805","title":"A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Ajax Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07319026","title":"Role of Myeloid-derived Suppressor Cells In Primary Myelofibrosis","phase":"","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Fondazione IRCCS Policlinico San Matteo di Pavia","has_results":false},{"nct_id":"NCT04217993","title":"Jaktinib for the Treatment of Ruxolitinib Intolerance of Myelofibrosis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","has_results":false},{"nct_id":"NCT02515630","title":"Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":41,"lead_sponsor_name":"Sierra Oncology LLC - a GSK company","has_results":true},{"nct_id":"NCT03935555","title":"Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Samus Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07340138","title":"Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":6,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04283526","title":"Study of Select Combinations in Adults With Myelofibrosis","phase":"PHASE1","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04745637","title":"Managed Access Programs for INC424, Ruxolitinib","phase":"","overall_status":"AVAILABLE","enrollment_count":null,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}